{"id":"https://openalex.org/W4387826006","doi":"https://doi.org/10.1016/j.annonc.2023.09.651","title":"475P Dynamics of TROP2 expression in triple-negative breast cancer","display_name":"475P Dynamics of TROP2 expression in triple-negative breast cancer","publication_year":2023,"publication_date":"2023-10-01","ids":{"openalex":"https://openalex.org/W4387826006","doi":"https://doi.org/10.1016/j.annonc.2023.09.651"},"language":"en","primary_location":{"id":"doi:10.1016/j.annonc.2023.09.651","doi":"https://doi.org/10.1016/j.annonc.2023.09.651","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2023.09.651","pdf_url":"http://www.annalsofoncology.org/article/S0923753423014874/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"http://www.annalsofoncology.org/article/S0923753423014874/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024995771","display_name":"Ana Christina Garrido-Castro","orcid":"https://orcid.org/0000-0002-5989-6636","observed_orcids":["https://orcid.org/0000-0002-5989-6636"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A.C. Garrido-Castro","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042886213","display_name":"Jorge G\u00f3mez Tejeda Za\u00f1udo","orcid":"https://orcid.org/0000-0002-1092-0068","observed_orcids":["https://orcid.org/0000-0002-1092-0068"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Gomez Tejeda Zanudo","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"J. Navarro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Navarro","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5092871642","display_name":"Alice Barkell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A.M. Barkell","raw_affiliation_strings":["Translational Science, AstraZeneca, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Translational Science, AstraZeneca, Cambridge, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":null,"display_name":"A. Frangieh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Frangieh","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031854515","display_name":"Ayesha Mohammed-Abreu","orcid":"https://orcid.org/0009-0000-2711-9624","observed_orcids":["https://orcid.org/0009-0000-2711-9624"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Mohammed-Abreu","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015055171","display_name":"Melissa E. Hughes","orcid":"https://orcid.org/0000-0001-6190-9101","observed_orcids":["https://orcid.org/0000-0001-6190-9101"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M.E. Hughes","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071007701","display_name":"Busem Binbo\u011fa Kurt","orcid":"https://orcid.org/0000-0002-7161-1496","observed_orcids":["https://orcid.org/0000-0002-7161-1496"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B. Binboga Kurt","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"R.J. Hill","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"R.J. Hill","raw_affiliation_strings":["Translational Science, AstraZeneca, Little Chesterford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Translational Science, AstraZeneca, Little Chesterford, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076310424","display_name":"Tari A. King","orcid":"https://orcid.org/0000-0003-3602-2351","observed_orcids":["https://orcid.org/0000-0003-3602-2351"]},"institutions":[{"id":"https://openalex.org/I4210161994","display_name":"Dana-Farber Brigham Cancer Center","ror":"https://ror.org/05rgrbr06","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I4210161994","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T.A. King","raw_affiliation_strings":["Surgery, Dana Farber/Brigham and Women's Cancer Center, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Surgery, Dana Farber/Brigham and Women's Cancer Center, Boston, MA, USA","institution_ids":["https://openalex.org/I4210161994"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029062544","display_name":"Elizabeth Ann Mittendorf","orcid":"https://orcid.org/0000-0002-9762-8536","observed_orcids":["https://orcid.org/0000-0002-9762-8536"]},"institutions":[{"id":"https://openalex.org/I4210161994","display_name":"Dana-Farber Brigham Cancer Center","ror":"https://ror.org/05rgrbr06","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I4210161994","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E.A. Mittendorf","raw_affiliation_strings":["Surgery, Dana Farber/Brigham and Women's Cancer Center, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Surgery, Dana Farber/Brigham and Women's Cancer Center, Boston, MA, USA","institution_ids":["https://openalex.org/I4210161994"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109358604","display_name":"Marlon Cezar Rebelatto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M.C. Rebelatto","raw_affiliation_strings":["Precision Medicine, AstraZeneca, Gaitherburg, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Precision Medicine, AstraZeneca, Gaitherburg, MD, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046909219","display_name":"Danielle K. Carroll","orcid":"https://orcid.org/0009-0002-0297-4119","observed_orcids":["https://orcid.org/0009-0002-0297-4119"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D. Carroll","raw_affiliation_strings":["Translational Science, AstraZeneca, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Translational Science, AstraZeneca, Cambridge, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022319770","display_name":"NU Lin","orcid":"https://orcid.org/0000-0003-2263-5413","observed_orcids":["https://orcid.org/0000-0003-2263-5413"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N.U. Lin","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S.M. Tolaney","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5059721552","display_name":"Elza C. de Bruin","orcid":"https://orcid.org/0000-0002-8996-8354","observed_orcids":["https://orcid.org/0000-0002-8996-8354"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"E.C. De Bruin","raw_affiliation_strings":["Translational Science, AstraZeneca, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Translational Science, AstraZeneca, Cambridge, UK","institution_ids":["https://openalex.org/I105036370"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4060,"currency":"USD","value_usd":4060},"apc_paid":null,"fwci":0.2547,"has_fulltext":true,"cited_by_count":2,"citation_normalized_percentile":{"value":0.47116437,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":96},"biblio":{"volume":"34","issue":null,"first_page":"S380","last_page":"S381"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9692000150680542,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9692000150680542,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.02019999921321869,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trop2","display_name":"TROP2","score":0.9760000109672546},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.9980000257492065},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.7670000195503235},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.906000018119812}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9267163276672363},{"id":"https://openalex.org/C204232928","wikidata":"https://www.wikidata.org/wiki/Q899285","display_name":"Immunohistochemistry","level":2,"score":0.6743885278701782},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6273603439331055},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.5640048980712891},{"id":"https://openalex.org/C2775934546","wikidata":"https://www.wikidata.org/wiki/Q179991","display_name":"Biopsy","level":2,"score":0.4424078166484833},{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.44156506657600403},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.42967379093170166},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.42136719822883606},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.40383636951446533},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.33874160051345825},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.19476953148841858},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.annonc.2023.09.651","doi":"https://doi.org/10.1016/j.annonc.2023.09.651","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2023.09.651","pdf_url":"http://www.annalsofoncology.org/article/S0923753423014874/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.annonc.2023.09.651","doi":"https://doi.org/10.1016/j.annonc.2023.09.651","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2023.09.651","pdf_url":"http://www.annalsofoncology.org/article/S0923753423014874/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320308982","display_name":"American Society of Clinical Oncology","ror":"https://ror.org/04fy6j421"},{"id":"https://openalex.org/F4320332898","display_name":"Stand Up To Cancer","ror":"https://ror.org/01dmpb598"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4387826006.pdf","grobid_xml":"https://content.openalex.org/works/W4387826006.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4408301774","https://openalex.org/W4415939868","https://openalex.org/W4410809165","https://openalex.org/W7127278664","https://openalex.org/W4322771482","https://openalex.org/W2947652916","https://openalex.org/W4225424725","https://openalex.org/W7167979875","https://openalex.org/W7169495455","https://openalex.org/W4296970940"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2023-10-21T00:00:00"}